Cardarine GW 501516 is not actually a SARM (Selective Androgen Receptor Modulator) but a PPARδ (Peroxisome Proliferator-Activated Receptor delta) agonist. This chemical was developed in the late 1990s by GlaxoSmithKline and Ligand Pharmaceuticals. It was initially researched for the treatment of obesity, diabetes, lipid dyslipidemia, and cardiovascular diseases.
The primary reason athletes use Cardarine is its potential to enhance endurance and support fat loss. Here are the possible effects of Cardarine:
Cardarine was withdrawn from human trials due to concerns that it might increase the risk of cancer. Therefore, long-term use could pose serious health risks. Additionally, some research suggests that Cardarine may have adverse effects on the liver.
Değerlendirmeler
Henüz değerlendirme yapılmadı.